Brief: Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities
13/01/2025 14:22
Jan 13 (Reuters) - Denali Therapeutics Inc DNLI.O :
* DENALI THERAPEUTICS INC: PREPARING FOR COMMERCIAL LAUNCH
OF
TIVIDENOFUSP ALFA FOR HUNTER SYNDROME IN LATE 2025 OR EARLY 2026
* DENALI THERAPEUTICS INC: ANTICIPATES ITS CASH RUNWAY WILL
EXTEND
INTO 2028
Source text: ID:nGNX2kZ48Y
Further company coverage: DNLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers